Medications for alcohol use disorders: An overview
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Patients who suffer from alcohol use disorders (AUDs) usually go through various socio‐behavioral and pathophysiological changes that take place in the brain and other organs. Recently, consumption of unhealthy food and excess alcohol along with a sedentary lifestyle has become a norm in both developed and developing countries. Despite the beneficial effects of moderate alcohol consumption, chronic and/or excessive alcohol intake is reported to negatively affect the brain, liver and other organs, resulting in cell death, organ damage/failure and death. The most effective therapy for alcoholism and alcohol related comorbidities is alcohol abstinence, however, chronic alcoholic patients cannot stop drinking alcohol. Therefore, targeted therapies are urgently needed to treat such populations. Patients who suffer from alcoholism and/or alcohol abuse experience harmful effects and changes that occur in the brain and other organs. Upon stopping alcohol consumption, alcoholic patients experience acute withdrawal symptoms followed by a protracted abstinence syndrome resulting in the risk of relapse to heavy drinking. For the past few decades, several drugs have been available for the treatment of AUDs. These drugs include medications to reduce or stop severe alcohol withdrawal symptoms during alcohol detoxification as well as recovery medications to reduce alcohol craving and support abstinence. However, there is no drug that completely antagonizes the adverse effects of excessive amounts of alcohol. This review summarizes the drugs which are available and approved by the FDA and their mechanisms of action as well as the medications that are under various phases of preclinical and clinical trials. In addition, the repurposing of the FDA approved drugs, such as anticonvulsants, antipsychotics, antidepressants and other medications, to prevent alcoholism and treat AUDs and their potential target mechanisms are summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80949-6 · Cited by 5,501
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.322 · Cited by 3,878
Narcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095
Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81965-0 · Cited by 2,613
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873 · cited 1×
“It is also used for the treatment of neuropathic pain in diabetic neuropathy, post-herpetic neuralgia (Moore, Wiffen, Derry, Toelle, & Rice, 2014), central neuropathic pain, hot flashes and restless leg syndrome (Attal et al., 2010; Wijemanne & Jankovic, 2015).”
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Neumann, Wigger, Torner, Holsboer, & Landgraf (2000) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2000.00442.x · Cited by 452
Baskerville, T. A., & Douglas, A. J. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00154.x · Cited by 377 · cited 1×
“The effects of oxytocin (OT) have been reported by many laboratories in alcohol addiction as well as in some neuropsychiatric disorders and social behaviors (Baskerville & Douglas, 2010; Lee & Weerts, 2016).”
Muth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374 · cited 1×
“This medicine belongs to a serotonin norepinephrine reuptake inhibitors (SNRI) group of inhibitors (Bymaster et al., 2001; Muth et al., 1986; Yardley et al., 1990) that increase the concentrations of the neurotransmitters serotonin and NE in the body and the brain.”
Sinha, R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.49 · Cited by 368
Pharmacological interventions for promoting smoking cessation during pregnancy
Coleman, T., Chamberlain, C., Davey, M.-A., Cooper, S. E., & Leonardi-Bee, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010078.pub2 · Cited by 357
Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11950 · Cited by 340
Roberto, M., Cruz, M. T., Gilpin, N. W., Sabino, V., Schweitzer, P., Bajo, M., Cottone, P., Madamba, S. G., Stouffer, D. G., Zorrilla, E. P., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.007 · Cited by 336
Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats
Vendruscolo, L. F., Barbier, E., Schlosburg, J. E., Misra, K. K., Whitfield, T. W., Logrip, M. L., Rivier, C., Repunte-Canonigo, V., Zorrilla, E. P., Sanna, P. P., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0069-12.2012 · Cited by 319
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287
Breaking the loop: Oxytocin as a potential treatment for drug addiction
McGregor, I. S., & Bowen, M. T. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.001 · Cited by 268 · cited 1×
“Additionally, treatment with OT at 1 mg/kg for 2 weeks before the start of a two-bottle free choice paradigm provided evidence that there was a significantly lower ethanol preference in OT-treated than in control rats (McGregor & Bowen, 2012).”
Richards, J. K., Simms, J. A., Steensland, P., Taha, S. A., Borgland, S. L., Bonci, A., & Bartlett, S. E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1136-5 · Cited by 234
Role of orexin/hypocretin in reward-seeking and addiction: Implications for obesity
Cason, A. M., Smith, R. J., Tahsili-Fahadan, P., Moorman, D. E., Sartor, G. C., & Aston-Jones, G. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.03.009 · Cited by 229
Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals
Vendruscolo, L. F., Estey, D., Goodell, V., Macshane, L. G., Logrip, M. L., Schlosburg, J. E., McGinn, M. A., Zamora-Martinez, E. R., Belanoff, J. K., Hunt, H. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79828 · Cited by 218
Intranasal oxytocin blocks alcohol withdrawal in human subjects
Pedersen, C. A., Smedley, K. L., Leserman, J., Jarskog, L. F., Rau, S. W., Kampov‐Polevoi, A., Casey, R. L., Fender, T., & Garbutt, J. C. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01958.x · Cited by 196
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
Comparing topiramate with naltrexone in the treatment of alcohol dependence
Baltieri, D. A., Daró, F. R., Ribeiro, P. L., & De Andrade, A. G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02355.x · Cited by 145
Bell, R. L., Lopez, M. F., Cui, C., Egli, M., Johnson, K. W., Franklin, K. M., & Becker, H. C. (2015) · Addiction Biology · doi:10.1111/adb.12106 · Cited by 138 · cited 1×
“These findings support the usage of ibudilast as a potential treatment for alcohol dependent patients (Bell et al., 2016).”
Self-citationCellular and behavioral interactions of gabapentin with alcohol dependence
Roberto, M., Gilpin, N. W., O'Dell, L. E., Cruz, M. T., Morse, A. C., Siggins, G. R., & Koob, G. F. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-08.2008 · Cited by 126
Ray, L. A., Bujarski, S., Shoptaw, S., Roche, D. J., Heinzerling, K., & Miotto, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.10 · Cited by 118
Oxytocin for the treatment of drug and alcohol use disorders
Lee, M. R., & Weerts, E. M. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000258 · Cited by 105 · cited 2×
“The effects of oxytocin (OT) have been reported by many laboratories in alcohol addiction as well as in some neuropsychiatric disorders and social behaviors (Baskerville & Douglas, 2010; Lee & Weerts, 2016).”
Brown, R. M., Khoo, S. Y.-S., & Lawrence, A. J. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000333 · Cited by 101
Simms, J. A., Haass-Koffler, C. L., Bito-Onon, J., Li, R., & Bartlett, S. E. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.268 · Cited by 97
Oxytocin reduces ethanol self-administration in mice
King, C. E., Griffin, W. C., Luderman, L. N., Kates, M. M., McGinty, J. F., & Becker, H. C. (2017) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13359 · Cited by 89 · cited 1×
“Systemic administration of OT reduces alcohol preference and intake in a variety of drinking models in rats (MacFadyen et al., 2016) and mice (King et al., 2017).”
Peripheral oxytocin administration reduces ethanol consumption in rats
MacFadyen, K., Loveless, R., DeLucca, B., Wardley, K., Deogan, S., Thomas, C., & Peris, J. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.10.014 · Cited by 76
for the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group, Ryan, M. L., Falk, D. E., Fertig, J. B., Rendenbach-Mueller, B., Katz, D. A., Tracy, K. A., Strain, E. C., Dunn, K. E., Kampman, K., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.214 · Cited by 72
Bordia, T., Hrachova, M., Chin, M., McIntosh, J. M., & Quik, M. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194852 · Cited by 70
Acamprosate: a review of its use in alcohol dependence
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0423-9 · Cited by 65 · cited 2×
“Thus, the use of acamprosate as an adjunct to psychosocial interventions in alcohol-dependent patients provides modest but potentially valuable improvements in alcohol-consumption outcomes (Plosker, 2015).”
Lopez, M. F., Moorman, D. E., Aston-Jones, G., & Becker, H. C. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.049 · Cited by 62
The oxytocin receptor impairs ethanol reward in mice
Bahi, A. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.11.046 · Cited by 55 · cited 2×
“Modulation of the OTR via administration of the OTR agonist carbetocin or gene over-expression of OTRs via a lentiviral vector in NAc resulted in reduced acquisition and ethanol-primed reinstatement of CPP as well as increased rates of extinction (Bahi, 2015).”
Brown, E. S., Davila, D., Nakamura, A., Carmody, T. J., Rush, A. J., Lo, A., Holmes, T., Adinoff, B., Caetano, R., Swann, A. C., et al. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12445 · Cited by 50 · cited 1×
“…with bipolar disorder (I and II) with depression and mixed mood state and alcohol dependence patients who were randomized and given quetiapine (600 mg/day) for 12 weeks did not show Significant differences in reducing alcohol consumption in patients with bipolar disorders (Brown et al., 2014).”
Katz, D. A., Locke, C., Greco, N., Liu, W., & Tracy, K. A. (2017) · Brain and Behavior · doi:10.1002/brb3.628 · Cited by 37
Fredriksson, I., Jayaram-Lindström, N., Wirf, M., Nylander, E., Nyström, E., Jardemark, K., & Steensland, P. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.294 · Cited by 35 · cited 1×
“…mg/kg, the nonspecific effects of sedation decreased as guanfacine increased significant water intake, but not in alcohol-naïve rats, suggesting that guanfacine mediated effects are specific that improve prefrontal connectivity through modulation of glutamatergic neurons (Fredriksson et al., 2015).”
Corrêa Filho, J. M., & Baltieri, D. A. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.12.018 · Cited by 26
Yang, L., Wang, F., Wang, M., Han, M., Hu, L., Zheng, M., Ma, J., Kang, Y., Wang, P., Sun, H., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.066 · Cited by 19 · cited 1×
“Recent studies have demonstrated OTRs are associated with genetic polymorphisms and aggression in humans and animal models (Gerra et al., 2017; Karpova, Mikheev, Marysheva, Bychkov, & Proshin, 2016; Yang et al., 2017).”
Cited by
The Neuroscience of Drug Reward and Addiction
Volkow, N. D., Michaelides, M., & Baler, R. (2019) · Physiological Reviews · doi:10.1152/physrev.00014.2018 · Cited by 863
Preclinical and clinical evidence for suppression of alcohol intake by apremilast
Grigsby, K. B., Mangieri, R. A., Roberts, A. J., Lopez, M. F., Firsick, E. J., Townsley, K. G., Beneze, A., Bess, J., Eisenstein, T. K., Meissler, J. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci159103 · Cited by 64
“Despite growing knowledge of important genetic and molecular mechanisms, pharmacological treatment options for AUD have only minimally advanced since the US Food and Drug Administration (FDA) approval of acamprosate in 2004 (2, 3).”
Elison-Davies, S., Newsome, J., Jones, A., Davies, G., & Ward, J. (2022) · Health & Justice · doi:10.1186/s40352-022-00190-w · Cited by 13
Metadata
- Authors
- Akbar, M., Egli, M., Cho, Y.-E., Song, B.-J., & Noronha, A.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 185
- Pages
- 64-85
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2772522913
- Cited by
- 96
- References
- 46
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.